These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 27681963)

  • 1. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

  • 2. Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
    Kotze PG; Danese S
    Curr Med Chem; 2019; 26(2):246-247. PubMed ID: 30907307
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 4. Positioning biologics-A case-based discussion: Anti-tumor necrosis factor biological agents/biosimilars.
    Leong RW; Katelaris PH
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():14. PubMed ID: 30187561
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T; Letkovsky J
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
    Felice C; Pugliese D; Armuzzi A
    Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
    [No Abstract]   [Full Text] [Related]  

  • 7. Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease.
    Bhat S; Limdi JK; Cross RK; Farraye FA
    Dig Dis Sci; 2021 Aug; 66(8):2513-2532. PubMed ID: 34176024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars in inflammatory bowel disease: A review of post-marketing experience.
    Deiana S; Gabbani T; Annese V
    World J Gastroenterol; 2017 Jan; 23(2):197-203. PubMed ID: 28127193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
    Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
    Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilar Monoclonal Antibodies for Inflammatory Bowel Disease: Current Comfort and Future Prospects.
    Gecse KB; Lakatos PL
    Drugs; 2016 Oct; 76(15):1413-1420. PubMed ID: 27638739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
    de Ridder L; Waterman M; Turner D; Bronsky J; Hauer AC; Dias JA; Strisciuglio C; Ruemmele FM; Levine A; Lionetti P;
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):503-8. PubMed ID: 26154031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
    Zheng MK; Shih DQ; Chen GC
    World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab Versus Biosimilars for IBD: Is It Better to Fight Than Switch?
    Scott FI
    Dig Dis Sci; 2020 Aug; 65(8):2158-2160. PubMed ID: 32338328
    [No Abstract]   [Full Text] [Related]  

  • 16. Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?
    Buer L; Høivik ML; Medhus AW; Moum B
    Dig Dis; 2017; 35(1-2):74-82. PubMed ID: 28147370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
    Patel D; Park KT
    J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
    Gecse KB; Cumming F; D'Haens G
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biosimilars in inflammatory bowel disease].
    Siegmund B; Atreya R; Bokemeyer B; Kruis W; Mudter J; Sander C; Schreiber S; Reindl W; Zeissig S; Kucharzik T
    Z Gastroenterol; 2016 Nov; 54(11):1217-1222. PubMed ID: 27711946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.